Advances in the cellular immunological pathogenesis of type 1 diabetes

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 5, 2014, Pages 749-758

  Li, Min ^a   Song, Lu Jun ^a   Qin, Xin Yu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Autoimmune disease; Immunological mechanism; Islet cells; T lymphocyte; Type 1 diabetes

Indexed keywords

AUTOANTIGEN;

ANTIGEN PRESENTING CELL; DIABETES MELLITUS, TYPE 1; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; NATURAL KILLER CELL; PATHOLOGY;

ANTIGEN-PRESENTING CELLS; AUTOANTIGENS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL;

EID: 84900537736     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12270     Document Type: Article

References (137)

1. Oyarzun A, Lera L, Codner E, et al. High concentrations of anti-caspase-8 antibodies in Chilean patients with type 1 diabetes. Immunobiology. 2011; 216: 208-12.
2. Badami E, Sorini C, Coccia M, et al. Defective Differentiation of regulatory FoxP3(+) T Cells by small-intestinal dendritic cells in patients with type 1 diabetes. Diabetes. 2011; 60: 2120-4.
3. Vendrame F, Cataldo D, Ciarlo L, et al. In Type 1 Diabetes Immunocompetent cells are defective in IL-16 secretion. Scand J Immunol. 2012; 75: 127-8.
4. Grieco FA, Vendrame F, Spagnuolo I, et al. Innate immunity and the pathogenesis of type 1 diabetes. Semin Immunopathol. 2011; 33: 57-66.
5. Gepts W. Pathologic anatomy of pancreas in juvenile diabetes mellitus. Diabetes. 1965; 14: 619.
6. Van Belle TL, Coppieters KT, Von Herrath MG. Type 1 diabetes etiology, immunology, and therapeutic strategies. Physiol Rev. 2011; 91: 79-118.
7. Santamaria P. The long and winding road to understanding and conquering type 1 diabetes. Immunity. 2010; 32: 437-45.
8. Khadra A, Pietropaolo M, Nepom GT, et al. Investigating the role of T-cell avidity and killing efficacy in relation to type 1 diabetes prediction. PLoS ONE. 2011; 6: e14796.
9. Vaziri-Sani F, Delli AJ, Elding-Larsson H, et al. A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. J Immunol Methods. 2011; 371: 25-37.
10. Long AE, Gillespie KM, Rokni S, et al. Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis. Diabetes. 2012; 61: 683-6.
11. Kent SC, Chen YH, Bregoli L, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature. 2005; 435: 224-8.
12. Nakayama M, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature. 2005; 435: 220-3.
13. Odumosu O, Payne K, Baez I, et al. Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit. Immunobiology. 2011; 216: 447-56.
14. Marttila J, Huttunen S, Vaarala O, et al. T-cell reactivity to insulin peptide A1-12 in children with recently diagnosed type 1 diabetes or multiple beta-cell autoantibodies. J Autoimmun. 2008; 31: 142-8.
15. Yu LP, Robles DT, Abiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA. 2000; 97: 1701-6.
16. Harrison LC, Wentworth JM, Zhang Y, et al. Antigen-based vaccination and prevention of type 1 diabetes. Curr Diabetes Rep. 2013; 13: 616-23.
17. Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res. 2009; 25: 307-15.
18. Solimena M, Aggujaro D, MuntzeL C, et al. Association of GAD-65, but not of GAD-67, with the golgi-complex of transfected chinese-hamster ovary cells mediated by the n-terminal region. Proc Natl Acad Sci USA. 1993; 90: 3073-7.
19. Hagopian WA, Chelsen BM, Karlsen AE, et al. Autoantibodies in IDDM primarily recognize the 65, 000-M(r) rather than the 67, 000-M(r) isoform of glutamic-acid decarboxylase. Diabetes. 1993; 42: 631-6.
20. Jayakrishnan B, Hoke DE, Langendorf CG, et al. An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes. PLoS ONE. 2011; 6: e18411.
21. Oak S, Radtke J, Torn C, et al. Immunoglobulin subclass profiles of anti-idiotypic antibodies to GAD65Ab differ between type 1 diabetes patients and healthy individuals. Scand J Immunol. 2011; 74: 363-7.
22. Wang X, Zhang A, Liu Y, et al. Anti-Idiotypic Antibody Specific to GAD65 autoantibody prevents type 1 diabetes in the NOD mouse. PLoS ONE. 2012; 7: e32515.
23. Tian J, Dang H, Kaufman DL. Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted beta-cells in diabetic NOD mice. PLoS ONE. 2011; 6: e25337.
24. Ludvigsson J, Krisky D, Casas R, et al. GAD65 Antigen therapy in recently diagnosed type 1 diabetes mellitus. New Engl J Med. 2012; 366: 433-42.
25. Boettler T, Pagni PP, Jaffe R, et al. The clinical and immunological significance of GAD-specific autoantibody and 1-cell responses in type 1 diabetes. J Autoimmun. 2013; 44: 40-8.
26. Cai T, Fukushige T, Notkins AL, et al. Insulinoma-Associated Protein IA-2, a vesicle transmembrane protein, genetically interacts with UNC-31 CAPS and affects neurosecretion in caenorhabditis elegans. J Neurosci. 2004; 24: 3115-24.
27. Leslie R, Atkinson MA, Notkins AL. Antoantigens IA-2 and GAD in type I (insulin-dependent) diabetes. Diabetologia. 1999; 42: 3-14.
28. Nakajima K, Wu G, Takeyama N, et al. Insulinoma-associated protein 2-deficient mice develop severe forms of diabetes induced by multiple low doses of streptozotocin. Int J Mol Med. 2009; 24: 23-7.
29. Lampasona V, Petrone A, Tiberti C, et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes non insulin requiring autoimmune diabetes (NIRAD) 4. Diabetes Care. 2010; 33: 104-8.
30. Dang M, Rockell J, Wagner R, et al. Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol. 2011; 186: 6056-63.
31. Skarstrand H, Lernmark A, Vaziri-Sani F. Antigenicity and epitope specificity of ZnT8 autoantibodies in type 1 diabetes. Scand J Immunol. 2013; 77: 21-9.
32. Chimienti F, Devergnas S, Favier A, et al. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes. 2004; 53: 2330-7.
33. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. 2007; 104: 17040-5.
34. Li S, Li H, Chen B, et al. Identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from zinc transporter 8. Vaccine. 2013; 31: 1610-5.
35. Long AE, Gooneratne AT, Rokni S, et al. The role of autoantibodies to zinc transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European nicotinamide diabetes intervention trial (ENDIT) Cohort. J Clin Endocr Metab. 2012; 97: 632-7.
36. Mannering SI, Pang SH, Williamson NA, et al. The A-chain of insulin is a hot-spot for CD4(+) T cell epitopes in human type 1 diabetes. Clin Exp Immunol. 2009; 156: 226-31.
37. Singh B, Nikoopour E, Huszarik K, et al. Immunomodulation and regeneration of islet beta cells by cytokines in autoimmune type 1 diabetes. J Interf Cytok Res. 2011; 31: 711-9.
38. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999; 5: 285-94.
39. Lin MS, Tse HM, Delmastro MM, et al. A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice. Immunol Res. 2011; 50: 213-20.
40. Sharif S, Arreaza GA, Zucker P, et al. Regulatory natural killer T cells protect against spontaneous and recurrent type 1 diabetes. Ann N Y Acad Sci. 2002; 958: 77-88.
41. Ruffner MA, Robbins PD. Dendritic cells transduced to express interleukin 4 reduce diabetes onset in both normoglycemic and prediabetic nonobese diabetic mice. PLoS ONE. 2010; 5: e11848.
42. Tai NW, Yasuda H, Xiang YF, et al. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8 RIP-B7.1 mice. Clin Immunol. 2011; 139: 336-49.
43. Wang M, Yang L, Sheng XY, et al. T-cell vaccination leads to suppression of intrapancreatic Th17 cells through Stat3-mediated ROR gamma t inhibition in autoimmune diabetes. Cell Res. 2011; 21: 1358-69.
44. Azar ST, Tamim H, Beyhum HN, et al. Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease. Clin Diagn Lab Immun. 1999; 6: 306-10.
45. Marwaha AK, Crome SQ, Panagiotopoulos C, et al. Cutting edge increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol. 2010; 185: 3814-8.
46. Wong CK, Lit LCW, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus Implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008; 127: 385-93.
47. Crome SQ, Wang AY, Levings MK. Translational Mini-Review Series on Th17 Cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol. 2010; 159: 109-19.
48. Ryba-Stanislawowska M, Skrzypkowska M, Mysliwiec M, et al. Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes. Hum Immunol. 2013; 74: 701-7.
49. Lee IF, Wang XJ, Hao JQ, et al. B7-H4.Ig inhibits the development of Type 1 diabetes by regulating Th17 cells in NOD mice. Cell Immunol. 2013; 282: 1-8.
50. Honkanen J, Nieminen JK, Gao R, et al. IL-17 immunity in human type 1 diabetes. J Immunol. 2010; 185: 1959-67.
51. Bending D, De La Pena H, Veldhoen M, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest. 2009; 119: 565-72.
52. Kilshaw PJ, Brent L, Pinto M. Suppressor T-cells in mice made unresponsive to skin allografts. Nature. 1975; 255: 489-91.
53. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008; 133: 775-87.
54. Petzold C, Riewaldt J, Watts D, et al. Foxp3(+) regulatory T cells in mouse models of type 1 diabetes. J Diabetes Res. 2013; 2013: 940710.
55. Antvorskov JC, Fundova P, Buschard K, et al. Dietary gluten alters the balance of pro-inflammatory and anti-inflammatory cytokines in T cells of BALB/c mice. Immunology. 2013; 138: 23-33.
56. Kawamoto K, Pahuja A, Nettles A, et al. Downregulation of TGF-beta RII in Teffector cells leads to increased resistance to TGF-beta-mediated suppression of autoimmune responses in type I diabetes. Autoimmunity. 2012; 45: 310-9.
57. Ishigame H, Zenewicz LA, Sanjabi S, et al. Excessive Th1 responses due to the absence of TGF-beta signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc Natl Acad Sci USA. 2013; 110: 6961-6.
58. Rajagopalan G, Kudva YC, Sen MM, et al. IL-10-deficiency unmasks unique immune system defects and reveals differential regulation of organ-specific autoimmunity in non-obese diabetic mice. Cytokine. 2006; 34: 85-95.
59. Collison LW, Delgoffe GM, Guy CS, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 2012; 13: 115-290.
60. Bettini M, Castellaw AH, Lennon GP, et al. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes. 2012; 61: 1519-26.
61. Haseda F, Imagawa A, Murase-Mishiba Y, et al. CD4(+)CD45RA(-)FoxP3(high) activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol. 2013; 173: 207-16.
62. Zhang YX, Bandala-Sanchez E, Harrison LC. Revisiting regulatory T cells in type 1 diabetes. Curr Opin Endocrinol. 2012; 19: 271-8.
63. Gol-Ara M, Jadidi-Niaragh F, Sadria R, et al. The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis. Arthritis. 2012; 2012: 805875.
64. Lin XH, Chen MG, Liu Y, et al. Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int J Clin Exp Pathol. 2013; 6: 116-23.
65. Jana S, Campbell H, Woodliff J, et al. The type of responder T-cell has a significant impact in a human in vitro suppression assay. PLoS ONE. 2010; 5: e15154.
66. Tonkin DR, Haskins K. Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner. Eur J Immunol. 2009; 39: 1313-22.
67. Tarbell KV, Yamazaki S, Olson K, et al. CD25(+) CD4(+) T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004; 199: 1467-77.
68. Li L, Nishio J, van Maurik A, et al. Differential response of regulatory and conventional CD4(+) lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action? J Immunol. 2013; 191: 3694-704.
69. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010; 207: 1871-8.
70. Shameli A, Yamanouchi J, Tsai S, et al. IL-2 promotes the function of memory-like autoregulatory CD8+T cells but suppresses their development via FoxP3+Treg cells. Eur J Immunol. 2013; 43: 394-403.
71. Kornete M, Mason ES, Piccirillo CA. Immune regulation in T1D and T2D: prospective role of Foxp3+ treg cells in disease pathogenesis and treatment. Front Endocrinol. 2013; 4: 76.
72. Glisic S, Klinker M, Waukau J, et al. Genetic association of HLA DQB1 with CD4+CD25+ (high) T-cell apoptosis in type 1 diabetes. Genes Immun. 2009; 10: 334-40.
73. Glisic S, Ehlenbach S, Jailwala P, et al. Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls. Cell Tissue Res. 2010; 339: 585-95.
74. Marek-Trzonkowska N, Mysliwec M, Siebert J, et al. Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes. 2013; 14: 322-32.
75. Mikulkova Z, Praksova P, Stourac P, et al. Numerical defects in CD8(+)CD28(-) T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol. 2010; 262: 75-9.
76. Harty JT, Bevan MJ. Responses of CD8(+) T cells to intracellular bacteria. Curr Opin Immunol. 1999; 11: 89-93.
77. Sutherland A, Joller N, Michaud M, et al. IL-21 promotes CD8(+) ctl activity via the transcription factor T-bet. J Immunol. 2013; 190: 3977-84.
78. Clarke S. The critical role of CD40 CD40L in the CD4-dependent generation of CD8(+) T cell immunity. J Leukocyte Biol. 2000; 67: 607-14.
79. Ghazarian L, Diana J, Simoni Y, et al. Prevention or acceleration of type 1 diabetes by viruses. Cell Mol Life Sci. 2013; 70: 239-55.
80. Rasche S, Busick RY, Quinn A. GAD65-Specific Cytotoxic T lymphocytes mediate beta-cell death and loss of function. Rev Diabet Stud. 2009; 6: 43-53.
81. Katz J, Benoist C, Mathis D. Major histocompatibility complex class-i molecules are required for the development of insulitis in nonobese diabetic mice. Eur J Immunol. 1993; 23: 3358-60.
82. Bulek AM, Cole DK, Skowera A, et al. Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol. 2012; 13: 283-1521.
83. Fierabracci A. The potential of multimer technologies in type 1 diabetes prediction strategies. Diabetes Metab Res. 2011; 27: 216-29.
84. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012; 209: 51-60.
85. Chen XL, Bobbala D, Rodriguez GM, et al. Induction of autoimmune diabetes in non-obese diabetic mice requires interleukin-21-dependent activation of autoreactive CD8(+) T cells. Clin Exp Immunol. 2013; 173: 184-94.
86. Barral AM, Thomas HE, Ling EM, et al. SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J Autoimmun. 2006; 27: 166-73.
87. Jiang H, Canfield SM, Gallagher MP, et al. HLA-E restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest. 2010; 120: 3641-50.
88. O'Neill SK, Liu E, Cambier JC. Change you can B(cell)eive in recent progress confirms a critical role for B cells in type 1 diabetes. Curr Opin Endocrinol. 2009; 16: 293-8.
89. Cox SL, Silveira PA. Emerging roles for B lymphocytes in Type 1 diabetes. Expert Rev Clin Immunol. 2009; 5: 311-24.
90. Hampe CS. Protective role of anti-idiotypic antibodies in autoimmunity - lessons for type 1 diabetes. Autoimmunity. 2012; 45: 320-31.
91. Wong FS, Wen L, Tang M, et al. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes. 2004; 53: 2581-7.
92. Brodie GM, Wallberg M, Santamaria P, et al. B-cells promote intra-islet CD8+ cytotoxic T-cell survival to enhance type 1 diabetes. Diabetes. 2008; 57: 909-17.
93. Xu BH, Cook RE, Michie SA. alpha(4)beta(7) integrin/MAdCAM-1 adhesion pathway is crucial for B cell migration into pancreatic lymph nodes in nonobese diabetic mice. J Autoimmun. 2010; 35: 124-9.
94. Noorchashm H, Noorchashm N, Kern J, et al. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 1997; 46: 941-6.
95. Hu CY, Ding HN, Zhang XJ, et al. Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes. 2013; 62: 2849-58.
96. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Brief report - development of type 1 diabetes despite severe hereditary B-cell deficiency. New Engl J Med. 2001; 345: 1036-40.
97. Kim HS, Lee MS. Role of innate immunity in triggering and tuning of autoimmune diabetes. Curr Mol Med. 2009; 9: 30-44.
98. Jobim M, Chagastelles P, Salim PH, et al. Association of killer cell immunoglobulin-like receptors and human leukocyte antigen-C genotypes in South Brazilian with type 1 diabetes. Hum Immunol. 2010; 71: 799-803.
99. Rodacki M, Svoren B, Butty V, et al. Altered natural killer cells in type 1 diabetic patients. Diabetes. 2007; 56: 177-85.
100. Miyazaki A, Hanafusa T, Yamada K, et al. Predominance of lymphocytes-t in pancreatic-islets and spleen of pre-diabetic non-obese diabetic (NOD) mice - a longitudinal-study. Clin Exp Immunol. 1985; 60: 622-30.
101. Brauner H, Elemans M, Lemos S, et al. Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J Immunol. 2010; 184: 2272-80.
102. Gur C, Porgador A, Elboim M, et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol. 2010; 11: 121-37.
103. Rodacki M, Milech A, De Oliveira J. NK cells and type 1 diabetes. Clin Dev Immunol. 2006; 13: 101-7.
104. Chandy KG, Charles MA, Buckingham B, et al. Deficiency of monoclonal-antibody (leu7) defined nk-cells in newly diagnosed insulin-dependent diabetes-mellitus. Immunol Lett. 1984; 8: 89-91.
105. Qin HJ, Wang ZD, Du WT, et al. Killer cell Ig-like receptor (KIR) 3DL1 down-regulation enhances inhibition of type 1 diabetes by autoantigen-specific regulatory T cells. Proc Natl Acad Sci USA. 2011; 108: 2016-21.
106. Willcox A, Richardson SJ, Bone AJ, et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009; 155: 173-81.
107. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol. 2002; 80: 497-505.
108. Ganguly D, Haak S, Sisirak V, et al. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013; 13: 566-77.
109. Blanco P, Palucka AK, Pascual V, et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth F R. 2008; 19: 41-52.
110. Grohmann U, Fallarino FFAU, Bianchi R, et al. IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2, 3-dioxygenase. J Immunol. 2001; 167: 708-14.
111. Angelini F, Del Duca EFAU, Piccinini S, et al. Altered phenotype and function of dendritic cells in children with type 1 diabetes. Clin Exp Immunol. 2005; 142: 341-6.
112. Mollah ZU, Pai SFAU, Moore C, et al. Abnormal NF-kappa B function characterizes human type 1 diabetes dendritic cells and monocytes. J Immunol. 2008; 180: 3166-75.
113. Grohmann U, Fallarino FFAU, Bianchi R, et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med. 2003; 198: 153-60.
114. Gautreau L, Chabannes D, Heslan M, et al. Modulation of regulatory T cell-Th17 balance by plasmacytoid dendritic cells. J Leukocyte Biol. 2011; 90: 521-7.
115. Ouabed A, Hubert FX, Chabannes D, et al. Differential control of T regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventional spleen dendritic cells. J Immunol. 2008; 180: 5862-70.
116. Diana J, Gahzarian L, Simoni Y, et al. Innate immunity in type 1 diabetes. Discov Med. 2011; 11: 513-20.
117. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008; 9: 239-44.
118. Meyers AJ, Shah RR, Gottlieb PA, et al. Altered toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med. 2010; 88: 1221-31.
119. Jin Y, Chen XQ, Podolsky R, et al. APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes. Clin Immunol. 2009; 130: 272-9.
120. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010; 6: 158-66.
121. Kolb H, Luckemeyer K, Heise T, et al. The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial). PLoS ONE. 2013; 8: e72440.
122. Lee LF, Xu B, Michie SA, et al. The role of TNF-alpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation. Proc Natl Acad Sci USA. 2005; 102: 15995-6000.
123. Han G, Wang R, Chen G, et al. Interleukin-17-producing gamma delta plus T cells protect NOD mice from type 1 diabetes through a mechanism involving transforming growth factor-beta. Immunology. 2010; 129: 197-206.
124. Simoni Y, Diana J, Ghazarian L, et al. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin Exp Immunol. 2013; 171: 8-19.
125. Diana J, Brezar V, Beaudoin L, et al. Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med. 2011; 208: 729-45.
126. Blumenfeld HJ, Tohn R, Haeryfar SMM, et al. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol. 2011; 166: 121-33.
127. Li M, Song LJ, Gao XD, et al. Toll-like receptor 4 on islet beta cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes. Exp Mol Med. 2012; 44: 260-7.
128. Chen WH, Xie AN, Chan L. Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Transl Res. 2013; 161: 217-29.
129. Pozzilli P. Type 1 diabetes mellitus in 2011 heterogeneity of T1DM raises questions for therapy. Nat Rev Endocrinol. 2012; 8: 78-80.
130. Li S, Zhang M, Xiang F, et al. Dendritic cells expressing BTLA induces CD8(+) T cell tolerance and attenuates the severity of diabetes. Vaccine. 2011; 29: 7747-51.
131. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol. 2013; 9: 92-103.
132. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. New Engl J Med. 2002; 346: 1692-8.
133. LoCascio SA, Spinelli J, Kurtz J. Hematopoietic stem cell transplantation for the treatment of autoimmunity in type 1 diabetes. Curr Stem Cell Res Ther. 2011; 6: 29-37.
134. Bassi EJ, Moraes-Vieira P, Moreira-Sa C, et al. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes. 2012; 61: 2534-45.
135. Davis NE, Hamilton D, Fontaine MJ. Harnessing the immunomodulatory and tissue repair properties of mesenchymal stem cells to restore beta cell function. Curr Diabetes Rep. 2012; 12: 612-22.
136. Soltani N, Qiu H, Aleksic M, et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci USA. 2011; 108: 11692-7.
137. Azzi J, Moore RF, Elyaman W, et al. The novel therapeutic effect of phosphoinositide 3-kinase-gamma inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012; 61: 1509-18.